(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck & Co. has launched a late-stage study of Restoret, the key asset in its recent $1.3 billion acquisition of eye-drug company EyeBio. Merck on Wednesday said the Phase 2b/3 study will evaluate ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

Merck & Company Inc (NYSE:MRK) was up 10% YTD as of Friday, August 30 ’24, but had been up as much as 21% at various times through the 2nd quarter, but the Q2 ’24 earnings release put a big ...

A new study has found that concentrations of essential minerals inside rhino horns are too low to provide consumers with any health benefits, questioning their use in traditional Chinese medicine.

Earlier this summer, miners accidentally unearthed the mummified remains of a woolly rhino in a quarry in the rural Oymyakonsky District of Russia. The preserved mammal’s body included soft ...

20. Merck's BTK inhibitor last December failed to beat off-patent Aubagio on efficacy in MS trials, hitting confidence in the wider drug class. Sanofi on Monday only provided a brief summary of ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

Mer­ck said Thurs­day morn­ing it is dis­con­tin­u­ing two Phase 3 tri­als of Keytru­da, the world’s top-sell­ing med­i­cine, af­ter in­de­pen­dent da­ta mon­i­tor­ing … ...

A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...